<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00829777</url>
  </required_header>
  <id_info>
    <org_study_id>28.073-2</org_study_id>
    <secondary_id>PR#0830A</secondary_id>
    <secondary_id>IRB# 26.073-2</secondary_id>
    <nct_id>NCT00829777</nct_id>
  </id_info>
  <brief_title>Safety Study of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects</brief_title>
  <acronym>AIKO-150</acronym>
  <official_title>A Phase-I, Two-Stage, Double-Blind, Placebo-Controlled, Pharmacokinetic and Pharmacodynamic Trial of Low Doses of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>California Pacific Medical Center Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>California Pacific Medical Center Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of intravenous 6β-Naltrexol
      administered to opiate dependent subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- 6β-Naltrexol will have 13 hr half-life. Plasma collected</measure>
    <time_frame>-0-24 hrs post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>- 6β-Naltrexol pharmacokinetic profile in opioid-dependent population will be similar in non-opioid-dependent population. Plasma levels collected</measure>
    <time_frame>0-8 hrs post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>-6β-Naltrexol will have a lower potency in precipitating withdrawal and be better tolerated than Naloxone assessed by vital signs, objective/subjective ate Withdrawal Scales, Visual Analog Scales, Pupil Size and GI Motility measures</measure>
    <time_frame>0-8 hrs post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6β-Naltrexol dose-dependent increases to reverse methadone-induced bowel dysfunction. Plasma levels and Hydrogen Breath Tests</measure>
    <time_frame>0-8 hrs post dose</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Opiate Addiction</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6β-Naltrexol escalating doses from 0.05-0.5 mg IV</intervention_name>
    <description>Drug: Naloxone 0.1 mg IV/5 minutes to all subjects to determine tolerability to precipitated withdrawal during screening. Those that tolerate withdrawal proceed to Stage 1:
Drug: Lactulose 10 gm orally plus 3 IV infusions 30 minutes apart of Naloxone 0.1 mg IV and 2 placebo given randomly to all subjects. If tolerated, proceed to 5 additional medication dosing sessions with all subjects receiving oral Lactulose 10 GM plus IV escalating 6β-Naltrexol 0.05 mg, 0.15 mg, 0.5 mg with a randomized placebo.</description>
    <other_name>Naloxone</other_name>
    <other_name>6β-Naltrexol</other_name>
    <other_name>Lactulose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Opiate dependent males and females age 21-45 on stable doses of methadone

          -  Fluent English speaker

          -  Willing and able to give written consent

        Exclusion Criteria:

          -  Pregnancy or lactation

        FOR MORE DETAILS CONTACT THE RESEARCH CLINIC.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John E Mendelson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Pacific Medical Center Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CPMC Addiction &amp; Pharmacology Research Laboratory (APRL)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2009</study_first_submitted>
  <study_first_submitted_qc>January 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2009</study_first_posted>
  <last_update_submitted>September 14, 2009</last_update_submitted>
  <last_update_submitted_qc>September 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>John Mendelson, M.D., Principal Investigator</name_title>
    <organization>Addiction &amp; Pharmacology Research Laboratory, California Pacific Medical Center Research Institute</organization>
  </responsible_party>
  <keyword>Naloxone</keyword>
  <keyword>6β-Naltrexol</keyword>
  <keyword>Opioid-dependent</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>peripheral effects of withdrawal</keyword>
  <keyword>central effects of withdrawal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Naloxone</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

